Brazen Bio

Number of Employees

2

Cash

$90

Revenue

$0

Short Term Debt

$90

Cost of Goods

$0

Long Term Debt

$0

Net Income

$0

Company Description

Brazen Bio is independent of any academic, industry, or venture capital organization. We are "founder friendly first"—completely aligned with the success of Brazen Fellows. Our unique ecosystem revolves around reducing the frictions of being a biotech founder and providing access to support including administrative and laboratory assistance. Brazen Fellows can count on continued support beyond the completion of the program.

 

Key Deal Facts

Building an ecosystem to address unmet medical needs; actively recruiting underrepresented founders
Team involved in over a dozen FDA filings and supported by a growing world-class advisory team
State-of-the-art laboratory space at BioLabs LA at the Lundquist Institute
First cohort of Brazen Fellows in 2021
Thought experiment: Imagine being able to invest in Y Combinator in 2005... (results not guaranteed)

Management Team / Advisory Board Bios

Shawn Carbonell, MD PhD, Cofounder & CEO
Quit neurosurgery residency to found a biotech startup. Invented and developed a first-in-class cancer drug currently in phase 1 clinical trial.

Brent Witgen, PhD, Cofounder & CEO
Direct involvement in over a dozen drug and device regulatory filings across multiple areas of human disease. Built high-performing teams in the US, EU, and Asia.